CAMP4 Therapeutics (NASDAQ:CAMP) Now Covered by Oppenheimer

Oppenheimer began coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP) in a research note issued to investors on Monday, Marketbeat reports. The brokerage issued an outperform rating and a $15.00 price target on the Wireless communications provider’s stock.

Several other brokerages have also recently weighed in on CAMP. UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Piper Sandler restated an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Finally, JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.86.

CAMP4 Therapeutics Stock Up 0.2%

NASDAQ CAMP opened at $4.01 on Monday. The company has a 50-day moving average price of $4.17 and a 200-day moving average price of $4.24. CAMP4 Therapeutics has a 52 week low of $2.86 and a 52 week high of $7.75. The firm has a market capitalization of $251.63 million, a P/E ratio of -1.73 and a beta of 0.27.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. As a group, equities research analysts anticipate that CAMP4 Therapeutics will post -0.57 EPS for the current year.

Insider Buying and Selling at CAMP4 Therapeutics

In other news, Director Andrew J. Schwab sold 400,000 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the sale, the director directly owned 2,033,270 shares of the company’s stock, valued at $8,214,410.80. This represents a 16.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard A. Young acquired 16,378 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the transaction, the director directly owned 186,388 shares in the company, valued at approximately $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Insiders own 21.69% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Jupiter Topco LLC purchased a new stake in CAMP4 Therapeutics during the 2nd quarter valued at approximately $27,581,000. 5AM Venture Management LLC purchased a new position in shares of CAMP4 Therapeutics in the second quarter worth $25,647,928. Trails Edge Capital Partners LP purchased a new position in shares of CAMP4 Therapeutics in the second quarter worth $8,446,935. BlackRock Inc. bought a new position in shares of CAMP4 Therapeutics during the second quarter worth $7,185,000. Finally, SummitTX Capital L.P. bought a new position in shares of CAMP4 Therapeutics during the first quarter worth $1,497,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.